IQVIA Logo

Insight

HSPB8 Targeting and Modulation: A dual modality approach

Scientific poster presented at Oligonucleotide Therapeutics Society 2026, in Denver, CO.
HSPB8 Targeting and Modulation: A dual modality approach
Home / Insights / HSPB8 Targeting and Modulation: A dual modality approach

This poster describes a drug repurposing approach and antisense oligonucleotide (ASO) approach to develop an individualized therapy for a patient with HSPB8 myopathy, an ultra-rare genetic disorder characterized by muscle wasting and progressive weakness.  

 

Authors: Maria Blanca Torroba1, Hamed Janbazacyabar1, Gurvan Mahe1, Jeroen Esselink1, Miranda van Dijk1, Anke Essing1, Jody van Offenbeek1, Andre van Marle1, David F. Fischer2 & Roxana S. Redis1
1: IQVIA Laboratories, Leiden, Netherlands
2: IQVIA Laboratories, Cambridge, UK

 


Download Document